Atlas Trials

A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine SCTV01E-1 in Population Aged Above 18 Years

Clinical trial NCT05522829 · UNKNOWN

Trial details

NCT number
NCT05522829
Sponsor
Sinocelltech Ltd.
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
COVID-19SARS-CoV-2 Infection
Start date
2022-10-15
Primary completion
2022-12-15
Enrollment
400

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.